Biologically active additives in gout: opportunities and perspectives

In recent years, there has been a growing interest in the use of biologically active additives (BAA) in the comprehensive management of gout, thereby opening new avenues for both patients and healthcare providers. Gout, as a metabolic disorder, necessitates not only traditional pharmacological interventions but also additional strategies for managing serum uric acid (SUA) levels. BAAs may serve as an important adjunct to existing medical therapies, enabling the reduction of hyperuricemia, the frequency of arthritis flare-ups, and the improvement of patients' quality of life. Research indicates that components of BAAs can modulate inflammatory responses and exhibit diuretic effects, which is particularly relevant for patients with urate nephropathy. However, despite promising results, further clinical trials are required to confirm their safety and efficacy. It is important to note that the integration of BAAs into standard therapy necessitates a careful analysis of interactions with other medications. We are on the brink of a new era in gout treatment, and BAAs may occupy a significant position in this transformation.